Flow Cytometry for BSL 3

描述（由申请人提供）：本康复法案有限竞争：高端仪器资助计划（S10）申请的目的是确保资金用于购买特殊的BD FACSAria IITM系统高速平行细胞分选器，用于弗吉尼亚大学医学院流式细胞术核心设施（FCCF）的bsl3级传染性微生物工作。FCCF没有在BSL3条件下使用的细胞分选器，并且在大学70英里范围内没有其他分选器。FCCF是弗吉尼亚大学一个使用非常频繁的核心设施，它以服务收费的方式向大学社区提供与流式细胞术相关的服务，特别是向NIH资助的医学院研究人员提供服务。FCCF目前为来自27个不同部门的95个pi实验室的200多名研究人员提供服务。其中42个pi使用FCCF进行细胞分选。2009年5月，大多数生物防御和传染病研究人员将搬进新的Carter-Harrison医学研究大楼，其中包括广泛的最先进的BSL3和aBSL3实验室。所要求的分选机将被放置在Carter-Harrison大楼内专门用于细胞分选的BSL3实验室中。弗吉尼亚大学的生物防御研究是由超过25名教职员工进行的，他们每年得到NIH超过2000万美元的支持。有8个学院迫切需要bsl3级别的细胞分选能力。购买和实施新的小区分选机将1)允许FCCF满足目前未满足的BSL3小区分选需求，2)满足近期容量增加的预期需求，3)通过增加可用于分选的参数来增加UVA社区可用的服务。相关性：荧光活化细胞分选是当前生物医学研究中一项重要的基础技术，涉及多个学科。细胞分选被用于研究癌症、传染病、衰老、免疫学、神经科学和心血管疾病等相关问题的基础、临床和转化研究。UVA无法满足对BSL3细胞分选服务的需求，已经成为完成大量由NIH资助的研究项目的严重瓶颈。购买新的细胞分选机将缓解这一瓶颈，并扩大我们的能力。

DESCRIPTION (provided by applicant): The purpose of this Recovery Act Limited Competition: High-End Instrumentation Grant Program (S10) application is to secure funding to purchase a Special BD FACSAria IITM system high speed parallel cell sorter for BSL3-level work with infectious microorganisms for the Flow Cytometry Core Facility (FCCF) at the University of Virginia School of Medicine. The FCCF does not have a cell sorter for use under BSL3 conditions, and there is no other sorter within 70 miles of the University. The FCCF is a very heavily used core facility at the University of Virginia and provides flow cytometry related services on a fee for service basis to the University community in general and particularly to NIH funded investigators in the School of Medicine. The FCCF currently serves over 200 investigators from the laboratories of 95 PIs from 27 different departments. 42 of these PIs use the FCCF for cell sorting. In May 2009 the majority of biodefense and infectious diseases researchers will move into the new Carter-Harrison Medical Research Building, which includes extensive state-of-the-art BSL3 and aBSL3 labs. The requested sorter will be placed in a dedicated BSL3 laboratory for cell sorting in the Carter-Harrison Building. Biodefense research at the University of Virginia is conducted by more than 25 members of the faculty who are supported by over $20 million in NIH support annually. There are 8 faculties with immediate need for BSL3-level cell sorting capabilities. Purchase and implementation of the new cell sorter will 1) allow the FCCF to meet the currently unmet demand for BSL3 cell sorting, 2) meet anticipated requirements for increased capacity in the near future, and 3) increase services available to the UVA community by increasing the parameters available for sorting. Relevance: Fluorescence activated cell sorting is a technique of fundamental importance in current biomedical research and crosses many disciplines. Cell sorting is used by individuals doing basic, clinical and translational research working on problems related to cancer, infectious disease, aging, immunology, neuroscience and cardiovascular disease among many others. The inability to meet the demand for BSL3 cell sorting services at UVA has become a serious bottleneck to completing a wide variety of research projects funded in a large part by the NIH. Purchase of a new cell sorter will relieve this bottleneck and extend our capabilities.